A Phase 3 interventional study of Darolutamide (Nubeqa, BAY1841788) and Placebo in Prostate Cancer Non-Metastatic and Castration-Resistant, sponsored by Bayer. Completed at 404 sites in 36 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-28.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing darolutamide in Prostatic Neoplasms — 29 open to participants now, 40 under way, 10 of them phase 3. darolutamide · Prostatic Neoplasms.
Among the 59 studies testing darolutamide in Prostatic Neoplasms, this one has the largest enrollment, is the only one that started in 2014, is one of 12 in phase 3, and was the 4th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →29 of the 59 studies testing darolutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+ · Men only
Bayer · Sites in China
Ages 18+ · Men only
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+ · Men only
K36 Therapeutics, Inc. · Sites in United States
Ages 18+ · Men only
Region Stockholm · Sites in Sweden
Ages 18+ · Men only
By country, each count listing its studies:
darolutamide: first FDA approval 2019 (NUBEQA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 34 · Phase 3 14 · Phase 4 4
First in 2011; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,509 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 80 across the 59 interventional studies. Of the 19 that completed or were terminated, 11 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 59 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
75 studies in Prostatic Neoplasms by Bayer: 11 open now, 16 under way, 1 of them phase 3. Of 57 finished, 12 (21%) have results posted.
Among the 75 studies in Prostatic Neoplasms by Bayer, this one has the largest enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2014, is one of 8 in phase 3, and was the 25th registered.
Bayer’s Prostatic Neoplasms studies by the year they started, since 2004.
9 of the studies testing darolutamide in Prostatic Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT05794906Phase 3BayerA Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies | 2027-07-30 |
| NCT06173362University of California, DavisAbiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer | 2026-11 |
| NCT06627530Brazilian Clinical Research InstituteCOACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer | 2026-12 |
| NCT05762536Erasmus Medical CenterDocetaxel or Cabazitaxel With or Without Darolutamide in mCRPC | 2027-05 |
Add all 9 to your calendar (.ics) → With an account.
Among the 59 studies testing darolutamide in Prostatic Neoplasms, from their registry updates:
Among Bayer’s 75 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in patients with non-metastatic castration-resistant prostate cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equal to a total daily dose of 1200 mg.
Drug: Darolutamide (Nubeqa, BAY1841788)
Participants received matching placebo 2 tablets twice daily with food.
Drug: Placebo
Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg.
Also known as: ODM-201
Matching placebo 2 tablets twice daily with food.
Metastasis-Free Survival
Metastasis-Free Survival (MFS) is defined as the time from randomisation to evidence of metastasis or death from any cause, whichever occurs first (cut-off date 15 Nov 2019)
Time frame: From randomization to the time approximately 385 MFS events were observed (approximately 48 months)
Overall Survival - Primary Analysis
Overall Survival (OS) was defined as the time from randomization to death due to any cause.
Time frame: From randomization of the first subject to the time approximatively 140 death events were observed (approximately 48 months)
Time to Pain Progression - Primary Analysis
Time to pain progression (PP) is defined as time from randomization to pain progression, where progression is defined as an increase of 2 or more points from baseline in question 3 of the Brief Pain Inventory-Short Form questionnaire (BPI-SF) related to the worst pain in the last 24 hours taken as a 7-day average for post-baseline scores, or initiation of short or long-acting opioids for pain, whichever comes first. Initiation or change in the use of other non-opioid analgesics is not used in the analysis of pain progression.
Time frame: From randomization until last study treatment (assessed every 4 months) (approximately 48 months)
Time to Initiation of First Cytotoxic Chemotherapy for Prostate Cancer - Primary Analysis
The time to cytotoxic chemotherapy was defined as the time from randomization to the start of the first cytotoxic chemotherapy cycle.
Time frame: From randomization until last study treatment (assessed every 4 months) (approximately 48 months)
Time to First Symptomatic Skeletal Event (SSE) - Primary Analysis
The time to the first SSE was defined as the time from randomization to the occurrence of the first SSE.
Time frame: From randomization until last study treatment (assessed every 4 months) (approximately 48 months)
Overall Survival - Final Analysis
Overall Survival (OS) was defined as the time from randomization to death due to any cause. The final analysis was done at the time of the data cut-off (15 NOV 2019).
Time frame: From randomization of the first subject to the time approximatively 254 death events were observed (approximately 56 months)
Time to Pain Progression - Final Analysis
For time to pain progression, the analysis performed using the primary completion cut-off data (03 SEP 2018) was considered final and no new analysis was performed for time to pain progression.
Time frame: From randomization until last study treatment (assessed every 4 months) (approximately 48 months)
Time to Initiation of First Cytotoxic Chemotherapy for Prostate Cancer - Final Analysis
The time to cytotoxic chemotherapy was defined as the time from randomization to the start of the first cytotoxic chemotherapy cycle. The final analysis was done at the time of the data cut-off (15 NOV 2019).
Time frame: From randomization until initiation of first cytotoxic chemotherapy treatment (approximately 59 months)
Time to First Symptomatic Skeletal Event (SSE) - Final Analysis
The time to the first SSE was defined as the time from randomization to the occurrence of the first SSE. The final analysis was done at the time of the data cut-off (15 NOV 2019).
Time frame: From randomization until occurrence of first SSE event (approximately 59 months)
Study was conducted at multiple centers in 36 countries between 12 September 2014 (first participant first visit) and 14 June 2021 (last participant last visit).
| Milestone | Darolutamide (BAY1841788) | Placebo |
|---|---|---|
| Started | 955 | 554 |
| Completed | 591 | 170 |
| Not completed | 364 | 384 |
| Withdrew: Adverse event | 86 | 48 |
| Withdrew: Confirmed metastasis | 120 | 140 |
| Withdrew: Judgment of the investigator | 59 | 99 |
| Withdrew: Metastasis by local reading | 1 | 3 |
| Withdrew: Other reason | 6 | 2 |
| Withdrew: Personal reason | 77 | 85 |
| Withdrew: Protocol deviation | 14 | 7 |
| Withdrew: Not treated | 1 | 0 |
| Milestone | Darolutamide (BAY1841788) | Placebo |
|---|---|---|
| Started | 591 | 170 |
| Completed | 295 | 114 |
| Not completed | 296 | 56 |
| Withdrew: Adverse event | 41 | 11 |
| Withdrew: Confirmed metastasis | 1 | 0 |
| Withdrew: Judgment of the investigator | 29 | 2 |
| Withdrew: Metastasis by local reading | 138 | 27 |
| Withdrew: Other reason | 22 | 4 |
| Withdrew: Personal reason | 60 | 8 |
| Withdrew: Protocol deviation | 3 | 2 |
| Withdrew: Missing | 2 | 2 |
Metastasis-Free Survival (MFS) is defined as the time from randomisation to evidence of metastasis or death from any cause, whichever occurs first (cut-off date 15 Nov 2019)
| months | Darolutamide (BAY1841788) | Placebo |
|---|---|---|
| Metastasis-Free Survival | 40.37 (34.33 to NA) | 18.43 (15.51 to 22.34) |
Overall Survival (OS) was defined as the time from randomization to death due to any cause.
| months | Darolutamide (BAY1841788) | Placebo |
|---|---|---|
| Overall Survival - Primary Analysis | NA (44.45 to NA) | NA (NA to NA) |
Time to pain progression (PP) is defined as time from randomization to pain progression, where progression is defined as an increase of 2 or more points from baseline in question 3 of the Brief Pain Inventory-Short Form questionnaire (BPI-SF) related to the worst pain in the last 24 hours taken as a 7-day average for post-baseline scores, or initiation of short or long-acting opioids for pain, whichever comes first. Initiation or change in the use of other non-opioid analgesics is not used in the analysis of pain progression.
| months | Darolutamide (BAY1841788) | Placebo |
|---|---|---|
| Time to Pain Progression - Primary Analysis | 40.31 (33.21 to 41.20) | 25.36 (19.09 to 29.63) |
The time to cytotoxic chemotherapy was defined as the time from randomization to the start of the first cytotoxic chemotherapy cycle.
| months | Darolutamide (BAY1841788) | Placebo |
|---|---|---|
| Time to Initiation of First Cytotoxic Chemotherapy for Prostate Cancer - Primary Analysis | NA (NA to NA) | 38.21 (35.55 to 41.89) |
The time to the first SSE was defined as the time from randomization to the occurrence of the first SSE.
| months | Darolutamide (BAY1841788) | Placebo |
|---|---|---|
| Time to First Symptomatic Skeletal Event (SSE) - Primary Analysis | NA (NA to NA) | NA (NA to NA) |
Overall Survival (OS) was defined as the time from randomization to death due to any cause. The final analysis was done at the time of the data cut-off (15 NOV 2019).
| months | Darolutamide (BAY1841788) | Placebo |
|---|---|---|
| Overall Survival - Final Analysis | NA (56.14 to NA) | NA (46.91 to NA) |
For time to pain progression, the analysis performed using the primary completion cut-off data (03 SEP 2018) was considered final and no new analysis was performed for time to pain progression.
| months | Darolutamide (BAY1841788) | Placebo |
|---|---|---|
| Time to Pain Progression - Final Analysis | 40.31 (33.21 to 41.20) | 25.36 (19.09 to 29.63) |
The time to cytotoxic chemotherapy was defined as the time from randomization to the start of the first cytotoxic chemotherapy cycle. The final analysis was done at the time of the data cut-off (15 NOV 2019).
| months | Darolutamide (BAY1841788) | Placebo |
|---|---|---|
| Time to Initiation of First Cytotoxic Chemotherapy for Prostate Cancer - Final Analysis | NA (NA to NA) | NA (NA to NA) |
The time to the first SSE was defined as the time from randomization to the occurrence of the first SSE. The final analysis was done at the time of the data cut-off (15 NOV 2019).
| months | Darolutamide (BAY1841788) | Placebo |
|---|---|---|
| Time to First Symptomatic Skeletal Event (SSE) - Final Analysis | NA (NA to NA) | NA (NA to NA) |
Collected over From start of study drug administration until 30 days after last treatment (last cut-off date 14 JUN 2021). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Darolutamide (DB) | 155/954 (16.2%) | 251/954 (26.3%) | 673/954 (70.5%) |
| Darolutamide (DB+OL) | 224/954 (23.5%) | 367/954 (38.5%) | 742/954 (77.8%) |
| Placebo (DB) | 137/554 (24.7%) | 121/554 (21.8%) | 354/554 (63.9%) |
| Placebo+Darolutamide (CO) | 16/170 (9.4%) | 43/170 (25.3%) | 110/170 (64.7%) |
| Event | Darolutamide (DB) | Darolutamide (DB+OL) | Placebo (DB) | Placebo+Darolutamide (CO) |
|---|---|---|---|---|
| Urinary retentionRenal and urinary disorders | 16/954 | 33/954 | 20/554 | 6/170 |
| HaematuriaRenal and urinary disorders | 11/954 | 25/954 | 7/554 | 0/170 |
| PneumoniaInfections and infestations | 15/954 | 20/954 | 6/554 | 1/170 |
| Atrial fibrillationCardiac disorders | 8/954 | 9/954 | 3/554 | 3/170 |
| Cardiac failureCardiac disorders | 8/954 | 12/954 | 4/554 | 2/170 |
| Urinary tract infectionInfections and infestations | 7/954 | 12/954 | 0/554 | 1/170 |
| Myocardial infarctionCardiac disorders | 4/954 | 11/954 | 2/554 | 2/170 |
| HydronephrosisRenal and urinary disorders | 3/954 | 8/954 | 4/554 | 2/170 |
| Urinary tract obstructionRenal and urinary disorders | 7/954 | 11/954 | 3/554 | 1/170 |
| AnaemiaBlood and lymphatic system disorders | 3/954 | 8/954 | 0/554 | 1/170 |
| Event | Darolutamide (DB) | Darolutamide (DB+OL) | Placebo (DB) | Placebo+Darolutamide (CO) |
|---|---|---|---|---|
| FatigueGeneral disorders | 126/954 | 142/954 | 47/554 | 9/170 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 106/954 | 135/954 | 58/554 | 17/170 |
| Back painMusculoskeletal and connective tissue disorders | 92/954 | 118/954 | 52/554 | 9/170 |
| AnaemiaBlood and lymphatic system disorders | 60/954 | 93/954 | 28/554 | 7/170 |
| DiarrhoeaGastrointestinal disorders | 69/954 | 87/954 | 33/554 | 15/170 |
| HypertensionVascular disorders | 66/954 | 87/954 | 31/554 | 6/170 |
| ConstipationGastrointestinal disorders | 65/954 | 84/954 | 36/554 | 8/170 |
| Urinary tract infectionInfections and infestations | 44/954 | 73/954 | 31/554 | 12/170 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 60/954 | 71/954 | 19/554 | 5/170 |
| HaematuriaRenal and urinary disorders | 37/954 | 66/954 | 27/554 | 12/170 |
| Age, Continuous(years) | Darolutamide (BAY1841788) | Placebo | Total |
|---|---|---|---|
| Mean | 73.9 ± 7.8 | 73.2 ± 8.2 | 73.6 ± 8.0 |
| Sex: Female, Male(Participants) | Darolutamide (BAY1841788) | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 955 | 554 | 1509 |
| Race/Ethnicity, Customized(Participants) | Darolutamide (BAY1841788) | Placebo | Total |
|---|---|---|---|
| Asia | 122 | 71 | 193 |
| Black or African American | 28 | 24 | 52 |
| White | 760 | 434 | 1194 |
| Missing | 36 | 19 | 55 |
| Other | 9 | 6 | 15 |
Showing the first 100 of 404 sites across 36 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2014 to primary completion in Sep 2018, 47 months.
Results were first posted in Oct 2019, 1 year 1 month after primary completion.
Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 47 months is above that.
Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Darolutamide